Idiopathic Pulmonary Fibrosis Partnering - 2010-2015





Published: May 2015 | Pages: 100+

The Idiopathic Pulmonary Fibrosis Partnering 2010-2015 report provides understanding and access to the idiopathic pulmonary fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in idiopathic pulmonary fibrosis partnering deals
  • Top idiopathic pulmonary fibrosis deals by value
  • Deals listed by company A-Z, industry sector, stage of development, technology type

 

The Idiopathic Pulmonary Fibrosis Partnering 2010-2015 provides understanding and access to the idiopathic pulmonary fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides an analysis of idiopathic pulmonary fibrosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors idiopathic pulmonary fibrosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This data driven report contains over 25 links to online copies of actual idiopathic pulmonary fibrosis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of idiopathic pulmonary fibrosis partnering trends.

 

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

 

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

 

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

 

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of idiopathic pulmonary fibrosis technologies and products.

 

Report scope 

 

Idiopathic Pulmonary Fibrosis Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to idiopathic pulmonary fibrosis trends and structure of deals entered into by leading companies worldwide.

 

This data driven report includes:

 

  • Trends in idiopathic pulmonary fibrosis dealmaking in the biopharma industry since 2010
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 25 idiopathic pulmonary fibrosis deals
  • The leading idiopathic pulmonary fibrosis deals by value since 2010

 

In Idiopathic Pulmonary Fibrosis Partnering 2010-2015, the available deals are listed by:

 

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


 

 

 

Executive Summary 

 

Chapter 1 – Introduction 

 

Chapter 2 – Trends in idiopathic pulmonary fibrosis partnering 

 

2.1. Introduction

2.2. Idiopathic pulmonary fibrosis partnering over the years

2.3. Idiopathic pulmonary fibrosis partnering by deal type

2.4. Idiopathic pulmonary fibrosis partnering industry sector

2.5. Idiopathic pulmonary fibrosis partnering by stage of development

2.6. Idiopathic pulmonary fibrosis partnering by technology type

 

Chapter 3 – Average deal terms for idiopathic pulmonary fibrosis 

  

   3.1 Introduction

   3.2 Average deal terms for idiopathic pulmonary fibrosis

   3.3 Idiopathic pulmonary fibrosis headline values with median calculation

   3.4 Idiopathic pulmonary fibrosis upfront values with median calculation

   3.5 Idiopathic pulmonary fibrosis milestone values with median calculation

   3.6 Idiopathic pulmonary fibrosis royalty rates with median calculation

 

Chapter 4 – Active idiopathic pulmonary fibrosis dealmakers 

 

4.1. Introduction

4.2 Most active idiopathic pulmonary fibrosis dealmakers

4.3. Top idiopathic pulmonary fibrosis deals by value

4.4 Big pharma deal activity

4.5 Big biotech deal activity

 

Chapter 5 – Idiopathic pulmonary fibrosis dealmaking directory 

 

5.1. Introduction

5.2. Company A-Z

5.3. By deal type

5.4. By industry sector

5.5. By stage of development

5.6. By technology type

 

Chapter 6 – Partnering resource center 

 

6.1. Online partnering

6.2. Partnering events

6.3. Further reading on dealmaking

 

Appendices 

 

Appendix 1 – Deal type definitions

 

About Wildwood Ventures 

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

Order Form – Reports

Order Form – Subscription Access Products

 

Table of figures 

 

Figure 1: Idiopathic pulmonary fibrosis partnering since 2010

Figure 2: Idiopathic pulmonary fibrosis dealmaking activity– 2010 to 2015

Figure 3: Idiopathic pulmonary fibrosis partnering by deal type since 2010

Figure 4: Idiopathic pulmonary fibrosis partnering by industry sector since 2010

Figure 5: Idiopathic pulmonary fibrosis partnering by stage of development since 2010

Figure 6: Idiopathic pulmonary fibrosis partnering by technology type since 2010

Figure 7: Idiopathic pulmonary fibrosis deals with a headline value

Figure 8: Idiopathic pulmonary fibrosis deals with upfront payment values

Figure 9: Idiopathic pulmonary fibrosis deals with milestone payments

Figure 10: Idiopathic pulmonary fibrosis deals with royalty rates, %

Figure 11: Top idiopathic pulmonary fibrosis deals by value since 2010

Figure 12: Big pharma – top 50 – idiopathic pulmonary fibrosis deals 2010 to 2015

Figure 13: Big pharma idiopathic pulmonary fibrosis deal frequency – 2010 to 2015

Figure 14: Big biotech – top 50 – idiopathic pulmonary fibrosis deals 2010 to 2015

Figure 15: Big biotech idiopathic pulmonary fibrosis deal frequency – 2010 to 2015

Figure 16: Online partnering resources

Figure 17: Forthcoming partnering events

Figure 18: Deal type definitions